Works by Vakil, Jignesh

Results: 7

Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.

Published in:

Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-60938-4

By:

Rudman Spergel, Amanda K.;
Lee, Ivan T.;
Koslovsky, Kindra;
Schaefers, Kristi;
Avanesov, Andrei;
Logan, Douglas K.;
Hemmersmeier, John;
Ensz, David;
Stadlbauer, Daniel;
Hu, Bo;
Pucci, Alicia;
Vakil, Jignesh;
Paris, Robert;
Ananworanich, Jintanat;
Nachbagauer, Raffael

Publication type:

Article

No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.

Published in:

Advances in Therapy, 2023, v. 40, n. 1, p. 367, doi. 10.1007/s12325-022-02322-y

By:

Blauvelt, Andrew;
Wollenberg, Andreas;
Eichenfield, Lawrence F.;
Zhang, Haixin;
Sierka, Debra;
Khokhar, Faisal A.;
Vakil, Jignesh;
Shabbir, Arsalan;
Marco, Ainara Rodríguez;
Cyr, Sonya L.

Publication type:

Article

Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.

Published in:

Pediatric Drugs, 2021, v. 23, n. 5, p. 515, doi. 10.1007/s40272-021-00459-x

By:

Paller, Amy S.;
Wollenberg, Andreas;
Siegfried, Elaine;
Thaçi, Diamant;
Cork, Michael J.;
Arkwright, Peter D.;
Gooderham, Melinda;
Sun, Xian;
O'Malley, John T.;
Khokhar, Faisal A.;
Vakil, Jignesh;
Bansal, Ashish;
Rosner, Karli;
Shumel, Brad;
Levit, Noah A.

Publication type:

Article

Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.

Published in:

2023

By:

Silverberg, Jonathan I.;
Lynde, Charles W.;
Abuabara, Katrina;
Patruno, Cataldo;
de Benedetto, Anna;
Zhang, Haixin;
Thomas, Ryan B.;
Bégo-Le-Bagousse, Gaëlle;
Khokhar, Faisal A.;
Vakil, Jignesh;
Marco, Ainara Rodríguez;
Levit, Noah A.

Publication type:

Correction Notice

Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.

Published in:

American Journal of Clinical Dermatology, 2023, v. 24, n. 3, p. 469, doi. 10.1007/s40257-022-00754-4

By:

Silverberg, Jonathan I.;
Lynde, Charles W.;
Abuabara, Katrina;
Patruno, Cataldo;
de Benedetto, Anna;
Zhang, Haixin;
Thomas, Ryan B.;
Bégo-Le-Bagousse, Gaëlle;
Khokhar, Faisal A.;
Vakil, Jignesh;
Marco, Ainara Rodríguez;
Levit, Noah A.

Publication type:

Article

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.

Published in:

American Journal of Clinical Dermatology, 2022, v. 23, n. 3, p. 393, doi. 10.1007/s40257-022-00685-0

By:

Beck, Lisa A.;
Deleuran, Mette;
Bissonnette, Robert;
de Bruin-Weller, Marjolein;
Galus, Ryszard;
Nakahara, Takeshi;
Seo, Seong Jun;
Khokhar, Faisal A.;
Vakil, Jignesh;
Xiao, Jing;
Marco, Ainara Rodriguez;
Levit, Noah A.;
O'Malley, John T.;
Shabbir, Arsalan

Publication type:

Article

Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data.

Published in:

Pediatric Dermatology, 2022, v. 39, n. 2, p. 187, doi. 10.1111/pde.14909

By:

Paller, Amy S.;
Beck, Lisa A.;
Blauvelt, Andrew;
Siegfried, Elaine C.;
Cork, Michael J.;
Wollenberg, Andreas;
Chen, Zhen;
Khokhar, Faisal A.;
Vakil, Jignesh;
Zhang, Annie;
Bansal, Ashish;
Cyr, Sonya L.

Publication type:

Article